Press Releases
 
Filgrastim Market by Application, Trends and Growth Rate to 2026

, 12 October 2018 -- Filgrastim Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2018 - 2026

Granulocyte colony stimulating factor is referred as stimulating factor 3, which acts to increase production of stem cells and granulocytes. Filgrastim is a granulocyte colony stimulating factor (G-CSF) prepared by recombinant DNA technology and often used in the treatment of low blood neutrophils. It is also frequently used in conditions where lukapheresis with increased white blood cells is observed. Common adverse effects of Filgrastim include joint pain, chest pain, hair loss, and vomiting.

Filgrastim is a recombinant form of naturally occurring G-CSF and functions by stimulating neutrophil production. It was approved in the U.S. in 1991 for the treatment low blood neutrophils. The World Health Organization declared Filgrastim in the List of Essential Medicines as safe and most effective medicine. Filgrastim was first discovered by Amgen, Inc. and sold under the brand name Neupogen. Large number of biosimilar companies are engaged in the manufacture and marketing of Filgrastim across the world. Filgrastim costs around US$ 200 in the U.S, around GBP 50 in the U.K., and US$ 100 in developing countries.

Filgrastim is prescribed for neutropenia, which is caused due to bone marrow transplantation and chemotherapy. It has been considered a supportive therapy in various types of cancers. In the last decade, there has been significant increase in cancer prophylaxis in developed countries and awareness initiatives taken by governments to educate about early treatment. These factors are expected to fuel the growth of the global Filgrastim market. Approved biosimilars such as Grafeel, Colstim, Neukine, and Filcad, which are much cheaper and readily available in developing countries, are expected to fuel the growth of the global Filgrastim market.

Ongoing biosimilars research and strong pipeline drugs are likely to boost the growth of the global market during the forecast period. Increase in the number of cancer patients, particularly in developing countries such as China and India, is one of the key factors likely to propel the global Filgrastim market during the forecast period. However, high cost of branded biologics and stringent regulatory guidelines for the approval of biosimilars in developed countries act as major restraints of the global market.

Request Report Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=45486

The global Filgrastim market can be segmented based on type, distribution channel, and region. In terms of type, the market can be bifurcated into biologics and biosimilars. The biologics segment is expected to be driven by high sales of established brand Neupogen. Availability of Neupogen in developing countries and higher cost restrain the biologics segment. The biosimilars segment is expected to expand at a higher growth rate due to low cost and easy availability in developing countries. Based on distribution channel, the global Filgrastim market can be categorized into hospital pharmacies, retail pharmacies, and online pharmacies. High demand for biologics in hospitals across the globe is projected to propel the hospital pharmacies segment from 2018 to 2026.

The global Filgrastim market can be segmented into five key regions: Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America is expected to account for a major share of the global market owing to developed health care infrastructure and favorable reimbursement policies. Europe was the second largest market for Filgrastim in 2017. India, China, and Japan are the major markets for Filgrastim in Asia Pacific. The global Filgrastim market is fragmented, with presence of large number of companies with global reach.

Request for TOC @ https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=45486

Major players in the global Filgrastim market include Amgen Inc., F. Hoffmann-La Roche Ltd., Dr. Reddy’s Laboratories Ltd, Intas Pharmaceuticals, Cadila Pharmaceuticals, Lupin Limited, Emcure Pharmaceuticals Ltd., and Biocon.

# # #


Submitted by hawer on Friday, 12 October 2018 at 3:07 PM
Category: Health Care & Medical
 
Related News

Top Shelf Quality Airbrush Tans from Gotham Glow
Sunday, 9 Dec 2018

Eczema around the Face - The best way to Get it Beneath Manage
Saturday, 8 Dec 2018

Super Nerve Power | Fibromyalgia Relief Super Nerve Power and Super Brain Power
Saturday, 8 Dec 2018

Customers Can Now Purchase Ganoderma Lucidum Spore Oil & Ganoderma Lucidum Spore Powder To Complete
Saturday, 8 Dec 2018

Systemic Lupus Erythematosus Analysis, Clinical Trials and Developments
Saturday, 8 Dec 2018

Related Events

Antibody Engineering and Therapeutics
Sunday, 9 Dec 2018

Mayo Clinic Women's Imaging Review Course
Monday, 10 Dec 2018

Antigen-Specific Immune Tolerance Europe Summit
Monday, 10 Dec 2018

International Cannabinoid Derived Pharmaceuticals Summit
Monday, 10 Dec 2018

Intensive Care Society State of the Art Conference (SOA), London 2018
Monday, 10 Dec 2018

Latest News

Medical Courier Market Size, Share, Growth, Segmentation and Forecast 2018 To 2026: Credence Researc
Monday, 10 Dec 2018

“AJOUR”: The Best Shopping Portal for All Your Lingerie Needs
Monday, 10 Dec 2018

Virtual Reality Technology
Monday, 10 Dec 2018

Electric Bicycles Market – Growth, Future Prospects and Competitive Analysis, 2018 – 202
Monday, 10 Dec 2018

Epic Research Weekly Agri Commodity Report Of 10 December 2018
Monday, 10 Dec 2018

 
Want to get your press releases, event listings, and job ads on Scoopasia? Register now for a FREE account or login if you already have one!
Scoopasia v1.0b. Copyright © 2018
Today is Monday, 10 December 2018

About Scoopasia | FAQ | Privacy Policy | Contact Us

Press Releases
Event Listings
Job Listings
Arts & Entertainment
Architecture & Construction
Automotive & Travel
Business
Consumer Technology
Economy
Education
Enterprise Technology
Food & Fashion
Government & Policy
Health Care & Medical
Legal/Law
News & Media
Religion
Science & Research
Sports & Fitness
Login / Register
Get Scoopasia through RSS Feeds & Email Notifications!


Journalist's Toolbox
Hello journalist, welcome to Scoopasia--a powerful online resource for media information in Asia. Scoopasia has press releases and media events for every beat and industry. All content on Scoopasia is 100% FREE. You don't even need to login!

  • Scoop Line
    (Instant Information Request)
    The easiest way to ask questions and request information from the PR community.


  • Advanced Search
    Drill down, dig deep, for media information the way you want it.

  • Journalist's Resources
    Resources and tools you can't do without.

  • PR Tools
    Scoopasia Blog Search
    Search the largest handpicked collection of Asia's most prominent and influential blogs.


    Resources
  • PR Bookmarks
  • Web 2.0 Bookmarks
  • Media Bookmarks

    More Coming Soon...

  • Upcoming Events
  • Antibody Engineering and Therapeutics
  • XLIVE 2018 Event Tech Conference in Las Vegas - December 9th-12th
  • Mayo Clinic Women's Imaging Review Course
  • SPE International Heavy Oil Conference and Exhibition.
  • Intensive Care Society State of the Art Conference (SOA), London 2018

  • Latest Jobs
    Sorry, there are currently no entries posted here.